[1]李晶,刘小军,赵达△.康莱特软胶囊联合化疗治疗晚期卵巢癌的临床研究[J].西部中医药,2013,26(01):1-4.
 LI Jing,LIU Xiaojun,ZHAO Da.Clinical Study on KangLaiTe Soft Capsule and Chemotherapy in Treating Ovarian Cancer at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2013,26(01):1-4.
点击复制

康莱特软胶囊联合化疗治疗晚期卵巢癌的临床研究()
分享到:

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
26
期数:
2013年01期
页码:
1-4
栏目:
论著·临床论著
出版日期:
2013-01-15

文章信息/Info

Title:
Clinical Study on KangLaiTe Soft Capsule and Chemotherapy in Treating Ovarian Cancer at Advanced Stage
文章编号:
1004-6852(2013)01-0001-04
作者:
李晶1刘小军2赵达2△
1 兰州市第一人民医院妇产科,甘肃 兰州 730050;
2 兰州大学第一医院
Author(s):
LI Jing1 LIU Xiaojun2 ZHAO Da2△
1 Department of Obstetrics and Gynecology in the First People忆s Hospital of Lanzhou, lanzhou 730050, China;
2 The First Hospital of Lanzhou University
关键词:
卵巢癌晚期康莱特化疗
Keywords:
ovarian canceradvanced stage KangLaiTe soft capsule chemotherapy
分类号:
R737.31
文献标志码:
A
摘要:
目的:评价康莱特软胶囊联合化疗治疗晚期卵巢癌的疗效、毒副反应及对患者生活质量的影响。方法: 将 65 例晚期卵巢癌患者随机分为康莱特组和对照组。康莱特组采用 TC 方案(紫杉醇 + 卡铂)化疗联合康莱特软胶囊治疗,对照组仅采用 TC 方案化疗,观察近期疗效、毒副反应、生活质量及血清CA125正常化比率。结果:康莱特组有效率为 42.4%,疾病控制率 75.8%;对照组有效率为 40.6%,疾病控制率 62.5%。康莱特组有效率及疾病控制率均高于对照组,但 2 组比较差异无统计学意义(P>0.05);康莱特组在总体健康评分、卵巢癌 V28 评分、部分症状改善方面优于对照组;康莱特组骨髓抑制、恶心、呕吐、疲乏、肌肉关节疼痛等毒副反应发生率低于对照组。结论:康莱特软胶囊联合化疗治疗晚期卵巢癌化疗有效率高,化疗相关毒副反应轻,能有效提高患者生活质量。
Abstract:
Objective: To explore curative effects and toxicity of KangLaiTe soft capsule and chemotherapy in the treatment for ovarian cancer at advanced stage and life its influence on quality of the patients. Method: All 65 patients with ovarian cancer at advanced stage were randomized into KangLaiTe group and the control group.KangLaiTe group received TC plan (paclitaxel+carboplatin) and KangLaiTe soft capsule while the control group TC plan only. Therapeutic effect in the near future, toxicity, life quality and ratio of serum CA125 normalization were observed. Result: The effective rate of KangLaiTe group was 42.4% , control rate of disease 75.8% , higher than 40.6% and 62.5% of the control group. The differences of the comparisons showed no statistical meaning (P> 0.05);KangLaiTe group was superior to the control group in total health scale, V28 scale of ovarian cancer, improvements of symptom; KangLaiTe group was lower than the control group in incidence of adverse reaction and toxicity which manifested arrest of bone marrow, nausea, vomiting, lassitude, muscular and joint pain, etc. Conclusion: KangLaiTe soft capsule and chemotherapy are effective in treating ovarian cancer at advanced stage, could alleviate toxicity induced by chemotherapy and improve life quality of patients effectively.

参考文献/References:

[1] Hunn J,Rodriguez GC.Ovarian Cancer:etiology,riskfactors,and epidemiology[J].Clinical obstetrics andgynecology,2012,55(1):3-23.
[2] Du Bois A,Lück HJ,Meier W,et al.A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian
cancer[J].Journal of the National Cancer Institute,2003,95(17):1320-1329.
[3] Lu Y,Wu LQ,Dong Q,et al.Experimental study on the effect of KangLaiTe induced apoptosis of human hepatoma carcinoma cell HepG2[J].Hepatobiliary Pancreat Dis Int,2009,8(3):267-272.
[4] 梁铁军,秦成勇,谭艳蓉,等.康莱特抑制肝癌细胞 HepG2增殖的实验研究[J].中国肿瘤临床,2006,33(13):743-746.
[5] Qi F,Li A,Inagaki Y,et al.Chinese herbal medicinesas adjuvant treatment during chemo-or radio-therapy for cancer[J].Bioscience trends,2010,4(6):297-307.
[6] 乐杰.妇产科学[M].7 版.北京:人民卫生出版社,2008:125.
[7] Burger R,Brady M,Bookman M,et al.Phase Ⅲ trial of bevacizumab(BEV)in the primary treatment of advanced epithelial ovarian cancer(EOC),primary peritoneal cancer(PPC)or fallopian tube cancer(FTC):a gynecologic oncology group study[J].J Clin Oncol,2010,28(18 suppl):8-13.
[8] 刘小军,周永宁,赵达.贝伐单抗治疗恶性肿瘤不良反应的策略[J].国际肿瘤学杂志,2011,38(9):711-714.
[9] Hanahan D,Weinberg RA.Hallmarks of cancer:the next generation[J].Cell,2011,144(5):646-674.
[10]李明花,金佳鹤.施志明治疗卵巢癌的经验[J].2008,30(9):902-903.
[11]黄毅超,何志江,刘云军,等.紫杉醇联合顺铂腹腔给药治疗52 例晚期卵巢癌效果分析[J].中国现代医生,2012,6(21):33-34.
[12]吴鹏,郑智.卵巢癌复发预测研究进展[J].中国现代医生,2012,6(4):29-30.
[13]何志芳.炎症与妇科恶性肿瘤关系的研究进展[J].中国现代医生,2011,5(22):15-16

相似文献/References:

[1]李树建.扶正祛积汤联合CEF化疗方案治疗晚期乳腺癌40例临床研究[J].西部中医药,2013,26(09):1.
 LI Shujian.Clinical Study on FuZheng QuJiTang Combined with CEF Chemotherapy in Treating 40 Patients Suffering from Advanced Mammary Cancer[J].Western Journal of Traditional Chinese Medicine,2013,26(01):1.
[2]赵航,戴玮,张华军.顾护胃气法改善晚期恶性肿瘤患者生活质量观察[J].西部中医药,2014,27(05):83.
 ZHAO Hang,DAI Wei,ZHANG Huajun.Observation on Improving Life Quality of the Patients with Advanced Malignant Tumors by Protecting Stomach-Qi Method[J].Western Journal of Traditional Chinese Medicine,2014,27(01):83.
[3]郭强蕊.CT诊断在卵巢癌和宫颈癌放射治疗前后的临床运用价值[J].西部中医药,2015,28(01):125.
[4]狄晓鸿,吕瑞.TP化疗方案联合参芪扶正注射液治疗晚期卵巢癌的临床观察[J].西部中医药,2015,28(08):1.
[5]贡惠娟,赵玉娥,严春亚,等.循证护理对中晚期肺癌患者睡眠质量和自我护理能力的影响[J].西部中医药,2015,28(12):121.
[6]艾敬,王红燕,张硕.Orem自理模式对卵巢癌化疗患者生活质量的影响[J].西部中医药,2017,30(04):127.
 AI Jing,WANG Hongyan,ZHANG Shuo.Effect of Orem Self-care Model on Life Quality of Patients with Chemotherapy of Ovarian Cancer[J].Western Journal of Traditional Chinese Medicine,2017,30(01):127.
[7]潘素群,陆勤,丘爱平.人生回顾联合生命陪伴对肺癌晚期接收姑息治疗患者临床护理观察[J].西部中医药,2022,35(04):135.[doi:10.12174/j.issn.2096-9600.2022.04.32]
 PAN Suqun,LU Qin,QIU Aiping.Application of Life Review Combined with Life Companionship for Advanced Lung Cancer Patients Undergoing Palliative Treatment[J].Western Journal of Traditional Chinese Medicine,2022,35(01):135.[doi:10.12174/j.issn.2096-9600.2022.04.32]

备注/Memo

备注/Memo:
收稿日期:2012-08-20
作者简介:李晶(1965—),女,副主任医师,中华医学会甘肃分会围产医学专业委员会委员,中华医学会甘肃分会辅助生殖医学专业委员会委员。研究方向:妇产科疾病的诊治。
△通讯作者:赵达(1965—),男,主任医师,副教授,中国抗癌协会临床肿瘤专业委员会(CSCO)会员,甘肃省抗癌协会理事,甘肃省抗癌协会分子靶向治疗专业委员会主任委员,甘肃省抗癌协会大肠癌专业委员会委员,甘肃省抗癌协会胃癌专业委员会委员。研究方向:消化系统、呼吸系统、妇科、乳腺及男性泌尿系统恶性实体瘤的诊治。
更新日期/Last Update: 2013-01-14